Moleculera Labs Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Moleculera Labs's estimated annual revenue is currently $2.6M per year.(i)
  • Moleculera Labs's estimated revenue per employee is $155,000

Employee Data

  • Moleculera Labs has 17 Employees.(i)
  • Moleculera Labs grew their employee count by 6% last year.

Moleculera Labs's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
Operations ManagerReveal Email/Phone
3
Medical Relations CoordinatorReveal Email/Phone
4
Assistant Scientist, Clinical Laboratory TechnologistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.8M50%N/AN/A
#3
$17.4M1123%N/AN/A
#4
$0.8M50%N/AN/A
#5
$65.3M301-3%$42.5MN/A
#6
$7.9M514%N/AN/A
#7
$2.8M180%N/AN/A
#8
$3.6M46-6%$14MN/A
#9
$1.4M90%N/AN/A
#10
$0.9M60%N/AN/A
Add Company

What Is Moleculera Labs?

Moleculera Labs offers advanced testing services in a fully-accredited CLIA/COLA clinical laboratory specializing in autoimmune neurobiology. As pioneers focusing on neuropsychiatric disorders caused by molecular mimicry, we offer The Cunningham Panelâ„¢, an aid to a physician's diagnosis of autoimmune-based neuropsychiatric disorders. The Cunningham Panelâ„¢ helps identify whether an individual's neurologic/psychiatric symptoms, such as obsessive compulsive behaviors, tics, anxiety, attention deficit hyperactivity disorder, and sometimes behaviors associated with Autism Spectrum Disorders, could be caused by a treatable autoimmune condition triggered by common infections. Additional Moleculera Labs research is directed toward the autoimmune nature of other neuropsychiatric conditions such as depression, schizophrenia, and bipolar disorder.

keywords:N/A

N/A

Total Funding

17

Number of Employees

$2.6M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3M17-69%N/A
#2
$2.5M17N/AN/A
#3
$1.5M176%N/A
#4
$1.5M17N/AN/A
#5
$2.6M18-28%N/A